IASLC World Conference on Lung Cancer
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to IASLC World Conference on Lung Cancer — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds
About this event
IASLC World Conference on Lung Cancer (WCLC 2026) — Description
The IASLC World Conference on Lung Cancer (WCLC 2026) will bring together the global thoracic oncology community in Seoul, Republic of South Korea from September 12–15, 2026. Hosted under the theme “SCIENCE WITHOUT BOUNDARIES: UNITING THE WORLD AGAINST THORACIC CANCER”, WCLC 2026 is designed to accelerate learning and collaboration across research and clinical practice for lung cancer and related thoracic malignancies.
WCLC 2026 is positioned as a comprehensive, multidisciplinary meeting that supports knowledge exchange through a full scientific program including plenary sessions, workshops, debates, and interactive learning sessions. The conference also emphasizes international accessibility, with information highlighted on the official website indicating translation for all sessions in all languages, along with live captions for the 2026 program.
Attendees can expect an environment focused on the latest advances in thoracic cancer care. The conference will feature global experts presenting, discussing, and debating breakthrough developments, and it will provide multiple opportunities to connect across specialties and roles, from research and clinical perspectives to education and patient advocacy.
In addition to the scientific and educational programming, WCLC 2026 includes a large abstract-driven component and structured learning formats intended to promote cross-disciplinary understanding and practical knowledge transfer. The official site describes the meeting as bringing together 7,000+ international attendees with 130+ sessions and workshops and 2,300+ abstracts, reflecting the conference’s scale and global reach.
For participants planning travel, the official conference information includes preparation guidance for visiting Seoul, as well as an airfare partnership with United Airlines for eligible delegates.
WCLC 2026 also provides a clear framework of important dates for conference registration and abstract-related milestones, including: early registration ending June 12, 2026 and regular registration ending July 24, 2026. The official site also lists key deadlines for abstract acceptance notification and full abstract release.
Overall, WCLC 2026 is an international scientific and educational gathering created to help the thoracic oncology community advance lung cancer research and improve patient care through collaboration, exchange, and shared scientific progress.
Data sheet
IASLC World Conference on Lung Cancer – Event Attendee & Buyer Profile Analysis
Event Date: September 12–15, 2026
Location: Seoul, Republic of South Korea
Event Status: Upcoming
Research Date: July 1, 2026
Location: Seoul, Republic of South Korea
Event Status: Upcoming
Research Date: July 1, 2026
Event Overview
| Event Name | IASLC World Conference on Lung Cancer (WCLC 2026) |
| Event Date | September 12–15, 2026 |
| Event Status | Upcoming |
| Venue | Venue not clearly specified in the provided official website text |
| City | Seoul |
| State / Region | Seoul Capital Area |
| Country | Republic of South Korea |
| Organizer | International Association for the Study of Lung Cancer (IASLC) |
| Official Event Website | wclc.iaslc.org |
| Event Type | International scientific congress / medical conference / exhibition |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; Business Services |
| Audience Reach | Global |
| Estimated Attendance / Expected Footfall | 7,000+ international attendees (official website statement) |
| Attendance Data Reliability | High for the organizer-published expected attendance figure; venue-specific final footfall not independently verified |
| Main Purpose of Event | To convene the global lung cancer and thoracic oncology community for scientific exchange, education, clinical collaboration, abstract presentations, and industry engagement |
About the Event
The IASLC World Conference on Lung Cancer (WCLC 2026) is a major global medical congress focused on thoracic oncology, lung cancer research, diagnosis, treatment, and multidisciplinary care. The official event messaging emphasizes science, collaboration, and knowledge exchange across clinicians, researchers, nurses, advocates, and industry participants.
This event matters because it sits at the center of lung cancer innovation and care delivery, bringing together a highly specialized international audience with strong influence over research adoption, clinical guidelines, diagnostics, therapeutics, imaging, pathology, digital health, and hospital purchasing. It is highly relevant for B2B attendee list building, pharmaceutical and medtech targeting, healthcare procurement outreach, research partnerships, and scientific marketing.
1. Who Attends: Buyers / Attendees
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Clinical leaders | Hospitals, cancer centers, academic medical centers | Influence on therapeutic adoption, protocols, and technology selection | High-value targets for pharma, diagnostics, imaging, and care pathway solutions |
| Oncology procurement teams | Hospital supply chain and procurement departments | Evaluate vendors, contracts, and sourcing decisions | Relevant for medical devices, consumables, lab solutions, and software |
| Researchers and principal investigators | Universities, research institutes, cancer centers | Shape trial participation, study design, and technology evaluation | Important for CROs, data platforms, biospecimen services, and research tools |
| Pharma and biotech buyers | Oncology pharmaceutical companies, biotech firms | Commercial, medical affairs, and partnership decision-making | High relevance for sponsorships, research collaborations, and vendor sourcing |
| Diagnostic laboratory leaders | Pathology labs, molecular diagnostics companies | Influence instrument, assay, and workflow purchases | Strong fit for companion diagnostics, genomics, and lab automation vendors |
| Radiology / imaging leaders | Hospitals, imaging networks, academic centers | Select imaging tools, AI tools, and workflow systems | Relevant for imaging vendors, PACS, AI detection, and reporting solutions |
| Nursing and care pathway leaders | Cancer centers, hospitals, patient support organizations | Influence patient education, workflow, and care coordination | Relevant for patient engagement, remote monitoring, and support services |
| Payers and health economics stakeholders | Health systems, payer organizations, HTA groups | Influence access, reimbursement, and adoption decisions | Useful for evidence generation, outcomes, and market access vendors |
| Association and advocacy leaders | Cancer advocacy groups, professional societies | Community influence, partnership, and education programming | Relevant for sponsorship, education, and awareness campaigns |
| Media and scientific communications | Medical publishers, journalists, conference media teams | Shape dissemination and visibility | Useful for visibility, thought leadership, and PR reach |
2. Event Location and Attendee Geographic Origin
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Host city: Seoul | Local hospitals, universities, biotech, and medical institutions | Medium | Strong local presence due to accessibility and national healthcare concentration |
| Host region: Seoul Capital Area | Korean medical centers, pharma firms, diagnostics companies | High | Major concentration of healthcare and life sciences buyers |
| National reach: South Korea | National cancer centers, tertiary hospitals, universities, medtech firms | High | Likely strong domestic attendance from major clinical and research institutions |
| Asia-Pacific region | Japan, China, Singapore, Australia, Taiwan, Hong Kong, India, Southeast Asia | High | APAC is a core market for thoracic oncology research and care innovation |
| North America / Europe | Global cancer centers, pharma HQs, research institutes, advocacy groups | High | WCLC has an established international scientific audience |
| Global / international | Researchers, clinicians, sponsors, and exhibitors from multiple continents | Very High | Official site describes 7,000+ international attendees |
3. Audience Reach
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | The conference is positioned as a worldwide thoracic oncology meeting with international attendees, speakers, abstracts, and exhibitors. |
4. Sample Buyer Companies and Websites
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| National Cancer Center Korea | Government / cancer center | Major thoracic oncology institution in the host country | ncc.re.kr | Director, Head of Oncology, Procurement Manager | Strong Market Fit, Attendance Not Confirmed |
| Asan Medical Center | Hospital / cancer care | Large tertiary center with oncology and research needs | amc.seoul.kr | Oncology Director, Clinical Research Lead, Supply Chain Director | Strong Market Fit, Attendance Not Confirmed |
| Seoul National University Hospital | Academic medical center | Key clinical and research buyer for oncology innovation | snuh.org | Department Chair, PI, Research Administration, Procurement | Strong Market Fit, Attendance Not Confirmed |
| Samsung Medical Center | Hospital / advanced cancer center | High-end clinical buyer for oncology technology and drugs | samsunghospital.com | Medical Director, Lab Director, IT Director, Procurement | Strong Market Fit, Attendance Not Confirmed |
| Severance Hospital (Yonsei) | Academic medical center | Strong lung cancer research and clinical adoption potential | sev.iseverance.com | Oncology Lead, Research Coordinator, Purchasing Manager | Strong Market Fit, Attendance Not Confirmed |
| Mayo Clinic | Hospital / research institution | Global cancer care buyer and evidence-generation leader | mayoclinic.org | Oncology Chair, Innovation Director, Strategic Sourcing | Strong Market Fit, Attendance Not Confirmed |
| Memorial Sloan Kettering Cancer Center | Cancer center | Major thoracic oncology decision-maker and research buyer | mskcc.org | Medical Oncologist, Clinical Trials Director, Procurement | Strong Market Fit, Attendance Not Confirmed |
| MD Anderson Cancer Center | Cancer center | High-volume oncology, trial, and procurement stakeholder | mdanderson.org | Oncology Program Director, Sourcing Manager, Lab Director | Strong Market Fit, Attendance Not Confirmed |
| AstraZeneca | Pharmaceutical company | Oncology pipeline and scientific exchange relevance | astrazeneca.com | Medical Affairs, Brand Lead, Partnership Director | Strong Market Fit, Attendance Not Confirmed |
| Roche | Pharmaceutical / diagnostics | Therapeutics and diagnostics buyer in thoracic oncology | roche.com | Medical Director, Market Access, Diagnostics Partnerships | Strong Market Fit, Attendance Not Confirmed |
| Bristol Myers Squibb | Pharmaceutical company | Oncology stakeholder for partnerships and market intelligence | bms.com | Medical Affairs, Business Development, Scientific Communications | Strong Market Fit, Attendance Not Confirmed |
| Merck & Co. | Pharmaceutical company | Key oncology and immunotherapy buyer / sponsor prospect | merck.com | Oncology Lead, Alliance Manager, Market Access | Strong Market Fit, Attendance Not Confirmed |
| Siemens Healthineers | Medical technology company | Imaging, diagnostics, and workflow solutions for oncology | siemens-healthineers.com | Product Manager, Sales Director, Clinical Applications | Strong Market Fit, Attendance Not Confirmed |
| GE HealthCare | Medical technology company | Relevant for imaging, AI, and hospital technology buyers | gehealthcare.com | GM, Product Marketing, Enterprise Sales, Hospital Solutions | Strong Market Fit, Attendance Not Confirmed |
| Foundation Medicine | Molecular diagnostics company | Genomic testing and precision oncology relevance | foundationmedicine.com | Medical Affairs, Commercial Lead, Lab Partnerships | Strong Market Fit, Attendance Not Confirmed |
5. Job Profiles, Industries and Event Type
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Chief Medical Officer / Medical Director | Clinical Leadership | C-Level / VP | Drives adoption of therapies, protocols, and evidence-based tools |
| 2 | Head of Oncology / Thoracic Oncology Lead | Clinical Services | Director / VP | Core disease-area decision-maker and conference attendee |
| 3 | Director of Clinical Research | Research | Director | High influence on trial participation, vendors, and partnerships |
| 4 | Principal Investigator / Research Professor | Academic Medicine | Senior / Professor | Shapes evidence generation and scientific collaborations |
| 5 | Procurement Manager / Strategic Sourcing Manager | Procurement | Manager / Director | Evaluates suppliers, contracts, and purchasing decisions |
| 6 | Laboratory Director / Pathology Director | Diagnostics / Lab | Director / Senior Director | Key buyer for diagnostics, assay platforms, and workflow tools |
| 7 | Radiology Director / Imaging Lead | Imaging | Director / Senior Director | Relevant for imaging, AI, and PACS-related buying |
| 8 | Medical Affairs Director | Pharma / Biotech | Director / Senior Director | Important for industry sponsorship, education, and KOL engagement |
| 9 | Business Development Director / Partnerships Director | Commercial / Partnerships | Director / VP | Relevant for collaboration, licensing, and sponsor engagement |
| 10 | Operations Director / Facilities Director | Operations | Director | Influences hospital systems, service providers, and infrastructure purchases |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Hospital & Health Care | Core attendee base includes hospitals and cancer centers | Hospital procurement, clinical leadership, oncology programs |
| 2 | Pharmaceuticals | High relevance for lung cancer therapeutics and trials | Medical affairs, commercial, market access |
| 3 | Biotechnology | Precision oncology and translational science relevance | R&D, partnerships, clinical development |
| 4 | Medical Devices | Diagnostic and treatment equipment buyers are highly relevant | Imaging, biopsy, surgical, and hospital device sales |
| 5 | Biotechnology | Research-heavy audience and biomarker innovation | Discovery platforms and trial support services |
| 6 | Research | Conference is strongly research-driven | Academic, translational, and laboratory buyers |
| 7 | Information Technology & Services | Clinical data, AI, and workflow platforms are relevant | Healthtech, data management, interoperability |
| 8 | Medical Practice | Specialist clinicians and outpatient oncology practices may attend | Clinic-level services, patient workflow tools |
| 9 | Government Administration | Public hospitals, national cancer agencies, ministries | Public-sector procurement and policy |
| 10 | Biotechnology | Strong fit for biomarker, genomics, and trial sponsors | Scientific collaboration and vendor sourcing |
| 11 | Medical Devices | Hospital technology and imaging sales potential | Capital equipment and consumables |
| 12 | Market Research | Useful for oncology insights, HCP intelligence, and patient journey studies | Insights, analytics, and advisory services |
6. Estimated Attendance
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | 7,000+ | Confirmed by organizer | Official website event summary | Described as international attendees |
| Exhibitor count | Not publicly confirmed | Unconfirmed | Official website mentions international exhibitors but does not provide a final count in the supplied text | Attendance figure not publicly confirmed by the organizer for exhibitors |
| Buyer count | Not publicly confirmed | Unconfirmed | No official buyer count disclosed | Use attendee profiling rather than a fixed buyer list |
| Speaker count | Not publicly confirmed | Unconfirmed | Program states 130+ sessions and workshops, but not a final speaker count in the provided text | Use agenda and speaker pages for list building |
| Sponsor count | Not publicly confirmed | Unconfirmed | Official page lists confirmed industry supporters but not an aggregate number in the supplied text | Check sponsor directory for current-year confirmation |
| Historical attendance | Prior-year data not included in supplied official text | Not used | No verified historical count provided here | Current organizer-published estimate is the best available figure |
7. Key Focus Areas and Buyer Engagement
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Oncology therapeutics | Clinical efficacy, safety, and trial evidence | Scientific exchange, KOL meetings, medical education | Pharma, biotech, clinical research services |
| Companion diagnostics | Biomarker-based treatment selection | Meet with molecular pathology and lab decision-makers | Diagnostic assays, genomics, lab systems |
| Imaging and AI | Detection, staging, workflow efficiency | Showcase radiology AI and imaging analytics | Imaging equipment, AI software, PACS integrations |
| Clinical trials and research | Patient recruitment, study design, data quality | Partner with investigators, CROs, and trial sites | CRO, eConsent, EDC, RWE platforms |
| Hospital procurement | Supplier reliability, compliance, total cost | Meet purchasing teams and supply chain leads | Medical devices, consumables, software, services |
| Precision medicine | Personalized treatment pathways | Target clinicians and research leaders evaluating adoption | Genomics, biomarkers, decision support |
| Patient support and adherence | Better navigation, education, and follow-up | Connect with nursing, advocacy, and care management teams | Patient engagement platforms, support programs |
| Market access / HEOR | Evidence for reimbursement and adoption | Engage payer and pharma value teams | HEOR consulting, real-world evidence, analytics |
Lead Quality Assessment
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | Very High | The event attracts clinicians, researchers, hospitals, pharma, diagnostics, and health systems with real buying influence. |
| Decision-maker availability | High | Senior medical, research, procurement, and commercial leaders are likely present. |
| Data collection potential | High | Agenda, abstracts, exhibits, and industry pages are strong list-building inputs. |
| Apollo targeting potential | Very High | Clear industry, title, department, and geography filters exist for healthcare and life sciences. |
| Geographic targeting potential | High | Strong Seoul, Korea, APAC, North America, and Europe segmentation is practical. |
| Best outreach approach | Very High | Target KOLs, trial sponsors, hospital procurement, diagnostics, and pharma commercial teams with relevant scientific messaging. |
| Overall lead quality | Very High | A premium global medical congress with strong enterprise and institutional buying relevance. |
| Best use case | Attendee list sales, sponsor prospecting, healthcare account mapping, and account-based outreach | Best used for account targeting by institution, specialization, and seniority. |
| Limitations / risks | Venue not confirmed in the supplied text; attendee list not publicly posted in the provided source excerpt | Rely on official program, exhibitor, and abstract pages for current-year confirmation. |
Apollo.io Targeting Recommendation
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Hospital & Health Care; Pharmaceuticals; Biotechnology; Medical Devices; Research; Information Technology & Services; Government Administration | Capture the most relevant healthcare and life sciences buyers |
| Departments | Medical Affairs; Clinical; Research; Procurement; Supply Chain; Business Development; Partnerships; IT; Operations | Identify buying, influencing, and partnership functions |
| Seniority | Manager; Director; Senior Director; VP; C-Level; Professor; Head | Prioritize decision-makers and subject-matter leaders |
| Job titles | Oncologist; Medical Director; Clinical Director; Director of Research; Procurement Manager; Supply Chain Director; Lab Director; Pathology Director; Radiology Director; Business Development Director; Partnership Director | Support highly specific list building and outreach |
| Geography | South Korea; Seoul; Asia-Pacific; United States; Canada; United Kingdom; Germany; Japan; China; Singapore; Australia | Map domestic host-market and international delegations |
| Employee size | 51–200; 201–500; 501–1,000; 1,001–5,000; 5,001+ | Cover hospitals, pharma, and enterprise health systems |
| Keywords | lung cancer, thoracic oncology, oncology, immunotherapy, biomarker, molecular diagnostics, clinical trial, precision medicine, pathology, radiology | Refine prospects tied to the conference theme |
| Company type | Hospital; Academic medical center; Cancer center; Pharma; Biotech; Diagnostics company; Research institute; Public health agency | Focus on institutional buyers and scientific stakeholders |
| Revenue / funding | Higher-revenue enterprises; public institutions; funded research organizations | Prioritize budget-holding and partnership-capable accounts |
Suggested Apollo Search Logic: (oncology OR “lung cancer” OR thoracic) AND (hospital OR “cancer center” OR pharmaceutical OR biotechnology OR diagnostics) AND (director OR VP OR head OR manager OR “medical affairs” OR procurement OR research).
Client Fit Review Required
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
Sources & Verification Notes
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| IASLC WCLC 2026 Official Website | Official organizer source | Event dates, city, country, theme, attendance estimate, sessions, abstracts, exhibitor support, and event status | High |
| WCLC 2026 Registration, Housing & Travel | Official event page | Conference dates, registration timing, and travel context | High |
| WCLC 2026 Program | Official agenda page | Program scale, scientific focus, plenaries, workshops, and session structure | High |
| WCLC 2026 Advertising & Exhibits | Official exhibitor information page | Confirms industry support and exhibitor presence as an event component | High |
| WCLC 2026 Venue & City Information | Official event page | Intended venue and host-city logistics page reference | High |
| IASLC Main Organization Website | Organizer website | Organizer identity and association context | High |
| International Conference Services (ICS) | Conference secretariat / event services | Secretariat and event operations contact information | Medium |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to IASLC World Conference on Lung Cancer — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds